Navigation Links
OncoGenex Pharmaceuticals to Present at RBC Capital Markets' Healthcare Conference
Date:3/1/2010

BOTHELL, WA, and VANCOUVER, March 1 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the RBC Capital Markets' Healthcare Conference on a panel titled "Cancer: Improving Treatment Through Combination Therapy." The panel will be held at 8:00 a.m. Eastern Time on March 3, 2010 at the Palace Hotel in New York.

A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. A webcast replay will be available approximately two hours after the call and will be archived for 30 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase 3 trials in castrate resistant prostate cancer in 2010, and a third Phase 3 trial in non-small cell lung cancer in early 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

Back to top
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
2. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
3. OncoGenex Reports Third Quarter 2009 Financial Results
4. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
5. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
6. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
7. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
8. OncoGenex Reports Second Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
11. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
(Date:12/2/2016)... RICHMOND, BC , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader ... Test, to Kenya,s Pharmaceutical Association members. (Photo: ... ... , , ... Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
Breaking Biology Technology:
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):